Protein Binding and Drug Clearance

Overview

Journal Clin Pharmacokinet

Specialty Pharmacology

Date 1984 Jan 1

PMID 6705422

Citations 39

Authors

M Rowland

Affiliations

Soon will be listed here.

Abstract

Most drugs are given continuously. Clearance, the parameter which relates rate of elimination to drug concentration, is important because it defines the rate of administration required to maintain a plateau drug concentration. Together with the extent of distribution outside of plasma, clearance also determines the speed at which a drug is eliminated from the body. The sensitivity of organ clearance of a drug to changes in binding within blood depends on its unbound clearance. If unbound clearance is low, relative to organ blood flow, the extraction ratio (and clearance) will always be low and dependent on plasma binding. If the extraction ratio is high, elimination becomes perfusion rate-limited and clearance will be relatively insensitive to changes in binding, but oral bioavailability may exhibit dependence on binding if the liver is the major eliminating organ. A full insight into the implications of altered binding on pharmacokinetics requires a sound understanding of the physiology both of the eliminating organs and the distribution of drug within the body. Such information is steadily being acquired.

Citing Articles

1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in .

Khonde L, Muller R, Boyle G, Reddy V, Nchinda A, Eyermann C J Med Chem. 2021; 64(17):12790-12807.

PMID: 34414766 PMC: 10500703. DOI: 10.1021/acs.jmedchem.1c00837.

Physiologically based metformin pharmacokinetics model of mice and scale-up to humans for the estimation of concentrations in various tissues.

Zake D, Kurlovics J, Zaharenko L, Komasilovs V, Klovins J, Stalidzans E PLoS One. 2021; 16(4):e0249594.

PMID: 33826656 PMC: 8026019. DOI: 10.1371/journal.pone.0249594.

Evaluation of serum lidocaine/monoethylglycylxylidide concentration to assess shunt closure in dogs with extrahepatic portosystemic shunts.

Devriendt N, Serrano G, Croubels S, Stock E, Vandermeulen E, Paepe D J Vet Intern Med. 2021; 35(1):261-268.

PMID: 33432666 PMC: 7848304. DOI: 10.1111/jvim.16030.

Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Single-Dose, Matched Case-Control Study.

Masters J, LaBadie R, Salageanu J, Li J, Shaik N Clin Pharmacol Drug Dev. 2020; 10(7):707-717.

PMID: 33356019 PMC: 8359308. DOI: 10.1002/cpdd.897.

Potential implications of DMET ontogeny on the disposition of commonly prescribed drugs in neonatal and pediatric intensive care units.

Naji-Talakar S, Sharma S, Martin L, Barnhart D, Prasad B Expert Opin Drug Metab Toxicol. 2020; 17(3):273-289.

PMID: 33256492 PMC: 8346204. DOI: 10.1080/17425255.2021.1858051.

References

Oie S, Guentert T, Tozer T . Effect of saturable binding on the pharmacokinetics of drugs: a simulation. J Pharm Pharmacol. 1980; 32(7):471-7. DOI: 10.1111/j.2042-7158.1980.tb12971.x. View

SHAND D, Cotham R, Wilkinson G . Perfusion-limited of plasma drug binding on hepatic drug extraction. Life Sci. 1976; 19(1):125-30. DOI: 10.1016/0024-3205(76)90382-9. View

Gugler R, Shoeman D, Huffman D, Cohlmia J, AZARNOFF D . Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest. 1975; 55(6):1182-9. PMC: 301871. DOI: 10.1172/JCI108035. View

Meffin P, Robert E, Winkle R, Harapat S, Peters F, Harrison D . Role of concentration-dependent plasma protein binding in disopyramide disposition. J Pharmacokinet Biopharm. 1979; 7(1):29-46. DOI: 10.1007/BF01059439. View

Jansen J . Influence of plasma protein binding kinetics on hepatic clearance assessed from a "tube" model and a "well-stirred" model. J Pharmacokinet Biopharm. 1981; 9(1):15-26. DOI: 10.1007/BF01059340. View

Bass L, Robinson P, Bracken A . Hepatic elimination of flowing substrates: the distributed model. J Theor Biol. 1978; 72(1):161-84. DOI: 10.1016/0022-5193(78)90023-1. View

Levy G . Effect of plasma protein binding on renal clearance of drugs. J Pharm Sci. 1980; 69(4):482-3. DOI: 10.1002/jps.2600690437. View

FORKER E, Luxon B . Albumin helps mediate removal of taurocholate by rat liver. J Clin Invest. 1981; 67(5):1517-22. PMC: 370720. DOI: 10.1172/jci110182. View

Schary W, Rowland M . Protein binding and hepatic clearance: studies with tolbutamide, a drug of low intrinsic clearance, in the isolated perfused rat liver preparation. J Pharmacokinet Biopharm. 1983; 11(3):225-43. DOI: 10.1007/BF01061866. View

10.

Wilkinson G, SHAND D . Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975; 18(4):377-90. DOI: 10.1002/cpt1975184377. View

11.

Rowland M, Leitch D, Fleming G, Smith B . Protein binding and hepatic extraction of diazepam across the rat liver. J Pharm Pharmacol. 1983; 35(6):383-4. DOI: 10.1111/j.2042-7158.1983.tb02961.x. View

12.

Pang K, Rowland M . Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm. 1977; 5(6):625-53. DOI: 10.1007/BF01059688. View

13.

Trenk D, Jahnchen E . Effect of serum protein binding on pharmacokinetics and anticoagulant activity of phenprocoumon in rats. J Pharmacokinet Biopharm. 1980; 8(2):177-91. DOI: 10.1007/BF01065192. View

14.

Levy G, Yacobi A . Letter: Effect of plasma protein binding on elimination of warfarin. J Pharm Sci. 1974; 63(5):805-6. DOI: 10.1002/jps.2600630539. View

15.

Guentert T, Oie S . Effect of plasma protein binding on quinidine kinetics in the rabbit. J Pharmacol Exp Ther. 1980; 215(1):165-71. View

16.

Tozer T . Concepts basic to pharmacokinetics. Pharmacol Ther. 1981; 12(1):109-31. DOI: 10.1016/0163-7258(81)90077-2. View

17.

Bryson S, Lawrence J, Steele W, Campbell B, Elliott H, Sumner D . The influence of protein binding on disopyramide clearance. Eur J Clin Pharmacol. 1982; 23(5):453-6. DOI: 10.1007/BF00605997. View

18.

Hall S, Rowland M . Relationship between renal clearance, protein binding and urine flow for digitoxin, a compound of low clearance in the isolated perfused rat kidney. J Pharmacol Exp Ther. 1984; 228(1):174-9. View

19.

Higham C, Aarons L, Holt P, Lynch M, Rowland M . A chronic dose-ranging study of the pharmacokinetics of phenylbutazone in rheumatoid arthritic patients. Br J Clin Pharmacol. 1981; 12(2):123-9. PMC: 1401862. DOI: 10.1111/j.1365-2125.1981.tb01190.x. View

20.

Blaschke T . Protein binding and kinetics of drugs in liver diseases. Clin Pharmacokinet. 1977; 2(1):32-44. DOI: 10.2165/00003088-197702010-00003. View